A Pilot Study on the Efficacy and Safety of a Novel Synbiotic Formula (SGR11) in Patients With Inflammatory Bowel Disease (IBD)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: SGR11 synbiotic formula.
- Who it may be relevant to
- Registry conditions: Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC). Basic parameters: 18 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Hong Kong
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The goal of this clinical trial is to find out whether a synbiotic formula (SGR11) can improve symptoms and health measures in people with inflammatory bowel disease (IBD). The main questions it aims to answer are: * Does SGR11 lead to overall improvement in a participant's condition after 8 weeks, as measured by the Clinical Global Impression-Improvement Scale (CGI I)? * Is SGR11 safe and well tolerated in people with IBD? Participants will: * Take the study synbiotic formula (SGR11) daily for 8 weeks * Complete symptom and quality of life questionnaires * Provide stool samples and, if applicable, blood samples to measure inflammation and gut microbiome changes * Report any side effects that occur during the study
Detailed description
Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is characterized by chronic relapsing inflammation of the gastrointestinal tract driven by dysregulated immune responses to intestinal microbiota. Extensive evidence demonstrates that IBD is associated with marked gut microbiota dysbiosis, including loss of key short-chain fatty acid (SCFA)-producing taxa and enrichment of pro-inflammatory or mucosa-associated organisms. These microbial alterations contribute to impaired epithelial barrier integrity, shifts in microbial metabolite profiles, activation of mucosal immune pathways, and increased susceptibility to persistent intestinal inflammation. Additionally, IBS-like symptoms remain common among individuals with IBD, even during clinical remission, indicating ongoing functional and microbiota-related disturbances not fully addressed by conventional therapies.
Synbiotics, which combine probiotic and prebiotic components in a synergistic formulation, represent a promising therapeutic strategy targeting microbial and mucosal mechanisms relevant to IBD. Components within SGR11 have demonstrated potential in preclinical and clinical research to modulate intestinal inflammation, enhance epithelial barrier function, influence T-cell-mediated immune responses, improve microbial fermentation profiles, and support restoration of gut microbiota homeostasis. Prebiotic elements within synbiotic formulations may further promote beneficial microbial activity, reinforce mucosal structural integrity, and modulate host immune responses.
This pilot, single-arm clinical trial will evaluate the safety and preliminary efficacy of SGR11 over an 8-week intervention period in adults with IBD. The study will assess global clinical improvement, symptom indices, patient-reported outcomes, biochemical markers of intestinal inflammation and permeability, and gut microbiome composition and functional characteristics using stool-based assays
Interventions
- Other SGR11 synbiotic formula
SGR11 is a synbiotic dietary supplement formulated to support gut microbial balance and intestinal health. It contains a combination of probiotic and prebiotic components designed to act synergistically to enhance microbial diversity, promote beneficial fermentation activity, and support mucosal barrier function. Participants will take the study product daily for 8 weeks. This formulation is distinguished by its specific synbiotic composition and its intended effects on gut microbiota-related pa
Primary outcome measures
- Proportion of participants demonstrating overall clinical improvement at 8 weeks (CGI-I) [Time frame: 8 weeks after initiation of the study intervention]
Eligibility criteria
Inclusion criteria
- Individuals aged between 18-75
- Chinese ethnicity
- Confirmed diagnosis of ulcerative colitis (UC) with mild to moderate disease activity, defined as a Simple Clinical Colitis Activity Index (SCCAI) of 3-5
- On stable doses of IBD medication for ≥4 weeks prior to enrolment
- Ability to provide written informed consent
- Willingness to comply with study procedures
Exclusion criteria
- Severe active IBD requiring hospitalization
- Known history of severe organ failure (including decompensated cirrhosis, malignant disease, kidney failure, epilepsy, active serious infection, acquired immunodeficiency syndrome)
- Presence of an ileostomy or colostomy
- Severe comorbidities or immunocompromised states
- Known current sepsis
- Recent use of antibiotics, probiotics, or prebiotics within 4 weeks
- Known pregnancy or breastfeeding
- Known allergy or intolerance to study components
- Inability to receive oral fluids
- Participation in other interventional clinical trials within 30 days
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Hong Kong · 2 centers
- Prince of Wales Hospital — Hong Kong
- Prince of Wales Hospital — Hong Kong
Identifiers
NCT: NCT07411131 · IBD Synbiotic